Development of a Genetic Score as a Response Modifier for Changes in Weight, Body Composition, and Biochemical Parameters in Obese Adults Undergoing a Low-Energy High-Protein Diet Intervention (Gens-HiPro)
11 de agosto de 2026 atualizado por: Yovita Puri Subardjo, Gadjah Mada University
The goal of this clinical trial is to evaluate whether a genetic score (Gens-HiPro) acts as a response modifier for weight loss, body composition changes, and biochemical parameters in obese adults undergoing a low-energy high-protein diet intervention.
The main questions it aims to answer is:
Does the genetic score (Gens-HiPro) modify responses to changes in weight, body composition, and biochemical parameters following a 12-week low-energy high-protein diet?
Participants will:
- Undergo initial screening to determine eligibility based on inclusion and exclusion criteria
- Complete baseline data measurement, including demographic data, anthropometric measurements (weight, BMI, body composition), biochemical blood analysis (total cholesterol, triglycerides, HDL, LDL, CRP), dietary assessment.
- Attend a small-group educational session on general guidelines, portion control, plate model ("Isi Piringku"), and food weighing techniques for a low-energy high-protein diet.
- Receive a 60-90 minute nutritional counseling session led by a dietitian at the start of intervention
- Follow the prescribed 12-week low-energy high-protein diet, supported by an active messaging channel on weekdays for daily dietary consultations
- Participate in at least three in-person monitoring and evaluation visits scheduled every 3-4 weeks (at weeks 4, 8, and 12 or weeks 4, 7, 10 and 12)
- Complete post-intervention evaluations at the end of week 12, repeating all baseline anthropometric, biochemical, and dietary assessments.
Visão geral do estudo
Status
Ainda não está recrutando
Condições
Intervenção / Tratamento
Descrição detalhada
Subjects will be stratified or analyzed based on their genetic profile using the Gens-HiPro score to evaluate gene-diet interactions on weight loss outcomes.
Gens-HiPro Genetic Score: A genetic risk score calculated as the sum of the products of each selected single nucleotide variant's (SNV) allele score and its respective effect size (mean difference [MD] in weight loss between allele groups).
The selected genetic variants were screened and identified through a systematic review and meta-analysis, including: APOA1 rs670, CB2R/CNR2 rs3123554, FTO rs1421085, FTO rs9939609, MC4R rs17782313, and MTNR1B rs10830963.
An allele score of 0 is assigned if a specific genetic variant falls into the genotype group with a smaller mean difference in weight loss.
An allele score of 1 is assigned if the variant falls into the genotype group with a larger mean difference.
The effect size represents the mean difference in weight loss, calculated by subtracting the mean weight loss of the genotype group with the smaller MD from the mean weight loss of the genotype group with the larger MD.
Tipo de estudo
Intervencional
Inscrição (Estimado)
29
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Yovita Puri Subardjo, S.Gz., Dietisien, MPH
- Número de telefone: +628174100488
- E-mail: yovitapurisubardjo@mail.ugm.ac.id
Locais de estudo
-
-
Central Java
-
Banyumas, Central Java, Indonésia, 53122
- Integrated Health Science Building, Faculty of Health Sciences
-
Contato:
- Adendita Azmi Afiattami, S.Gz
- Número de telefone: +6285117481147
- E-mail: adendita.azmi@unsoed.ac.id
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Adult males or females aged 18 - 40 years.
- Classified as obese with a Body Mass Index (BMI) of 27 - 35 kg/m² and a waist circumference of ≥90 cm for men and ≥80 cm for women.
- Willing to adhere to the prescribed low-energy high-protein diet.
- Willing to undergo anthropometric measurements, body composition analysis, lipid profile testing, and genetic variation screening.
- Signed the written informed consent form.
Exclusion Criteria:
- Having chronic diseases that affect metabolism or body weight.
- Diagnosed with chronic kidney disease (CKD).
- Currently pregnant, lactating, or planning a pregnancy during the study period.
- Currently participating in an intensive weight loss program or receiving pharmacological therapy for weight loss within the last 3 months.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: low-energy high-protein diet intervention
Participants in this single-arm study will undergo a 12-week low-energy high-protein diet intervention (personalized nutritional counseling by a dietitian).
|
This intervention consists of a 12-week low-energy high-protein diet program delivered through structured behavioral and nutritional counseling. Nutrition care process: individual nutritional counseling, one-on-one counseling session conducted by a registered dietitian. The dietary regimen is prescribed with an energy deficit of 500-750 kcal/day, ensuring a minimum daily energy intake of 1.200 kcal/day for women and 1.500 kcal/day for men. Macronutrient distribution is targeted at 1.2-1.6 g/kg adjusted body weight for protein, 20-30% of total energy for fat, and 45-55% of total energy for carbohydrates. Genetic profiling using the Gens-HiPro score is conducted to evaluate its role as a modifier of outcome responses in weight loss, body composition, and biochemical parameters. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Body Weight
Prazo: 12 weeks
|
Body weight refers to the total body mass of the subject, measured using a weighing scale in kilograms (kg).
The change in body weight is calculated as the difference between the body weight value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Body Mass Index (BMI)
Prazo: 12 weeks
|
Body Mass Index is the ratio of the subject's body weight in kilograms divided by the square of their height in meters (kg/m²).
The change in BMI is calculated as the difference between the BMI value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
|
Change in Fat Mass
Prazo: 12 weeks
|
Fat mass is the total amount of fat present in the subject's body, measured using Bioelectrical Impedance Analysis (BIA).
The change in fat mass is calculated as the difference between the fat mass value in kg at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
|
Change in Muscle Mass
Prazo: 12 weeks
|
Muscle mass refers to the total amount of muscle (skeletal muscle mass) in the subject's body, measured using Bioelectrical Impedance Analysis (BIA).
The change in muscle mass is calculated as the difference between the muscle mass value in kg at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
|
Change in Visceral Fat
Prazo: 12 weeks
|
isceral fat is the fat stored within the abdominal cavity that surrounds the subject's internal organs, measured using Bioelectrical Impedance Analysis (BIA).
The change in visceral fat mass is calculated as the difference between the visceral fat mass value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
|
Change in Waist Circumference
Prazo: 12 weeks
|
Waist circumference is a simple physical measurement taken using a measuring tape (metline) around the abdomen to estimate central obesity, reported in centimeters (cm).
The change in waist circumference is calculated as the difference between the waist circumference value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Fasting Serum Triglycerides
Prazo: 12 weeks
|
Triglycerides refer to triacylglycerol molecules, measured via biochemical analysis of blood after a minimum 8-hour fast and reported in mg/dL.
The change in triglyceride values is calculated as the difference between the triglyceride value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
|
Change in Fasting Serum High-Density Lipoprotein (HDL) Cholesterol
Prazo: 12 weeks
|
HDL refers to small plasma lipoprotein particles, measured via biochemical analysis of blood after a minimum 8-hour fast and reported in mg/dL.
The change in HDL values is calculated as the difference between the HDL value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
|
Change in Fasting Serum Low-Density Lipoprotein (LDL) Cholesterol
Prazo: 12 weeks
|
LDL refers to low-density plasma lipoprotein particles, measured via biochemical analysis of blood after a minimum 8-hour fast and reported in mg/dL.
The change in LDL values is calculated as the difference between the LDL value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Note: Fixed a typo in your original text which stated "nilai HDL pada awal intervensi").
(Scale: Ratio)
|
12 weeks
|
|
Change in Fasting Serum Total Cholesterol
Prazo: 12 weeks
|
Total cholesterol is the concentration of all cholesterol contained within the lipoproteins circulating in the blood, measured enzymatically in serum/plasma and reported in mg/dL.
The change in total cholesterol values is calculated as the difference between the total cholesterol value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
|
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Prazo: 12 weeks
|
CRP is the measured concentration of an acute-phase protein produced by the liver in response to inflammatory cytokines, measured using a standard hs-CRP assay and reported in mg/dL.
The change in CRP values is calculated as the difference between the CRP value at the baseline of the intervention (Week 0) and the end of the intervention (Week 12).
(Scale: Ratio)
|
12 weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de setembro de 2026
Conclusão Primária (Estimado)
31 de dezembro de 2026
Conclusão do estudo (Estimado)
31 de janeiro de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
7 de agosto de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
7 de agosto de 2026
Primeira postagem (Real)
12 de agosto de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
13 de agosto de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
11 de agosto de 2026
Última verificação
1 de agosto de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 092/KEPK/PE/VII/2026 (Outro identificador: Health Research Ethics Committee, Faculty of Medicine, Universitas Jenderal Soedirman)
- 202406210804017 (Número de outro subsídio/financiamento: Indonesia Endowment Fund for Education Agency (LPDP RI))
- 548/UN1/FKKMK.3/S3KK.3/PJ/2026 (Outro identificador: Doctoral Program in Medical and Health Sciences, Faculty of Medicine, Public Health, and Nursing UGM)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
Individual participant data will not be shared to protect patient privacy and confidentiality, in accordance with the informed consent signed by the participants and the restrictions set by the Institutional Review Board (IRB) / Ethics Committee.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .